Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
AURA Aura Biosciences
- 7.930
- +0.160+2.06%
Close Jan 21 16:00 ET
- 7.950
- +0.020+0.25%
Post 20:01 ET
396.12MMarket Cap-4.58P/E (TTM)
7.990High7.670Low119.53KVolume7.670Open7.770Pre Close941.69KTurnover0.37%Turnover RatioLossP/E (Static)49.95MShares12.37852wk High2.27P/B253.28MFloat Cap6.63052wk Low--Dividend TTM31.94MShs Float26.160Historical High--Div YieldTTM4.12%Amplitude5.990Historical Low7.877Avg Price1Lot Size
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Aura Biosciences Stock Forum
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-SAR in Patients With Non-Muscle-Invasive Bladder Cancer (Nmibc) in Ongoing Phase 1 Trial! No adverse events
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Aura Biosciences (NASDAQ: AURA) reported positive Phase 2 end of study results for bel-sar (AU-011) in treating early-stage choroidal melanoma (CM). The study showed an 80% tumor control rate and 90% visual acuity preservationamong Phase 3-eligible patients. Bel-sar demonstrated a highly favorable safety profile with no tre...
via @Lnova 📊⚡️📊
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
In reaction to earnings/guidance:
• $Nutanix (NTNX.US)$ +15.4%, $Pure Storage (PSTG.US)$ +6.8%, $Credo Technology (CRDO.US)$ +5.9%, $Signet Jewelers (SIG.US)$ +3.6%, $SentinelOne (S.US)$ +3.4%, $Five Below (FIVE.US)$ +3.2%, $GMS Inc (GMS.US)$ +1.7%, $The Scotts Miracle (SMG.US)$ +0.9% (also CFO steps down, lowers FY22 FCF guidance, reaffirms all other guidance)
Other news:
• $Turquoise Hill Resources (TRQ.US)$ +12.3% (to be acquired by Rio T...
• $Aura Biosciences (AURA.US)$ +13.9% (reports topline data from study of AU-011)
• $Hyzon Motors (HYZN.US)$ +8.2% (to collaborate with $Schlumberger (SLB.US)$ in decarbonizing oil & gas field operations with high-power fuel cells)
• $Apogee Enterprises (APOG.US)$ +6.3% (In reaction to earnings/guidance)
• $GMS Inc (GMS.US)$ +6% (In reaction to earnings/guidance)
• $Darden Restaurants (DRI.US)$ +4.2% (In reaction to earnings/gui...
No comment yet